Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,869.50    18.00 (0.97%)
Bid:
1,869.00
Ask:
1,870.00
Spread: 1.00 (0.054%)
Market Cap: £74.98b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Total Voting Rights

1 Dec 2021 11:05

GLAXOSMITHKLINE PLC - Total Voting Rights

GLAXOSMITHKLINE PLC - Total Voting Rights

PR Newswire

London, December 1

GlaxoSmithKline plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the ‘Company’) hereby notifies the market of the following:

The Company’s issued share capital as at 30 November 2021 consisted of 5,386,985,162 shares of 25 pence each (‘Ordinary Shares’), of which 355,205,950 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 5,031,779,212. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

V A Whyte

Company Secretary

1 December 2021

Date   Source Headline
1st Apr 20263:30 pmRNSDirector/PDMR Shareholding
1st Apr 20263:00 pmRNSTotal Voting Rights
1st Apr 20267:00 amRNSViiV completes changes to minority shareholding
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:05 amRNSBepirovirsen accepted for review in China
30th Mar 20267:00 amRNSExdensur approved for severe asthma in China
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSBepirovirsen accepted for review by the EMA
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20263:30 pmRNSDirector/PDMR Shareholding
25th Mar 20261:00 pmRNSNotice of AGM
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20263:30 pmRNSDirector/PDMR Shareholding
23rd Mar 20263:00 pmRNSAdmission to Trading
23rd Mar 20267:00 amRNSGSK Lung Cancer ADC Gets Japan Orphan Drug Status
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 202612:00 pmRNSLynavoy (linerixibat) approved by US FDA
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20263:30 pmRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 202610:31 amRNSUS FDA approves Arexvy for adults 18-49 AIR
13th Mar 202610:31 amRNSUS FDA approves Arexvy for adults 18-49 AIR
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20263:00 pmRNSBoard Committee Change
9th Mar 20263:00 pmRNSBoard Committee Change
9th Mar 20267:00 amRNSGSK and Alfasigma agree global linerixibat rights
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20262:21 pmRNSFiling of GSK plc 2025 Annual Report on Form 20-F
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 202610:00 amRNSGSK publishes Annual Report 2025
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20263:30 pmRNSDirector/PDMR Shareholding
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20263:00 pmRNSGSK completes acquisition of RAPT Therapeutics
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20263:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.